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Shay Tzur1, Walter G Wasser2,3, Saharon Rosset4† and Karl Skorecki1,3,5*†Abstract
Background: A recent meta-analysis described a variant (p.Ile2984Val) in the cubilin gene (CUBN) that is associated
with levels of albuminuria in the general population and in diabetics.
Methods: We implemented a Linkage Disequilibrium (LD) search with data from the 1000 Genomes Project,
on African and European population genomic sequences.
Results: We found that the p.Ile2984Val variation is part of a larger haplotype in European populations and it is
almost absent in west Africans. This haplotype contains 19 single nucleotide polymorphisms (SNPs) in very high LD,
three of which are missense mutations (p.Leu2153Phe, p.Ile2984Val, p.Glu3002Gly), and two have not been
previously reported. Notably, this European haplotype is absent in west African populations, and the frequency of
each individual polymorphism differs significantly in Africans.
Conclusions: Genotyping of these variants in existing African origin sample sets coupled to measurements of urine
albumin excretion levels should reveal which is the most likely functional candidate for albuminuria risk. The unique
haplotypic structure of CUBN in different populations may leverage the effort to identify the functional variant and
to shed light on evolution of the CUBN gene locus.Background
Albumin excretion is tightly regulated by the kidney so
that under normal circumstances, virtually no albumin
appears in the urine [1]. Albuminuria, when present due
to kidney disease, is strongly associated with increased
risk for cardiovascular disease and mortality [2], as well
as progression to end stage kidney disease [3]. Albumin-
uria is additive to other kidney risk factors such as dia-
betes and hypertension [2,4,5], and multiple mechanisms
for its pathogenesis have been proposed [6,7].* Correspondence: skorecki@tx.technion.ac.il
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reproduction in any medium, provided the orA variant in the cubilin gene (CUBN) that is associated
with albuminuria has been recently reported by Boger
et al. [8]. This gene encodes the cubilin receptor, which
is a peripheral membrane protein expressed in the renal
proximal tubule [9,10]. It is part of the megalin-cubilin
complex receptor, responsible for the reabsorption of al-
bumin [6] and other proteins present in the glomerular
ultrafiltrate, minimizing their excretion in healthy
human urine [6,10,11]. In addition, cubilin is also re-
sponsible for the vital conservation of vitamins and trace
elements [10]. Rare mutations in the CUBN gene can
cause hereditary megaloblastic anemia and proteinuria
(Imerslund-Grasbeck syndrome) [12].
Boger et al. reported a statistical association of the com-
mon CUBN missense variation p.Ile2984Val (rs1801239,
c.8950A>G) with both an elevated urinary albumin-to-. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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buminuria (P=0.001), in population sample sets including
non-diabetic and diabetic subjects [8]. This study reported
a large meta-analysis of data from a total of 63,153 indivi-
duals of European ancestry and 6,981 African-Americans.
The CUBN missense variation p.Ile2984Val was also asso-
ciated with an increased risk of persistent microalbumi-
nuria in 1,304 patients of European ancestry prospectively
followed with Type 1 Diabetes Mellitus (T1DM) , with an
estimated hazard ratio per copy of the risk allele of 1.42
(p=0.02) [8]. It should be noted that the allele frequency
of this variant according to HapMap [13] is 7.5% in
Europeans and 1.8% in west Africans of Yoruba ancestry
(YRI).
The recent availability of complete genomic sequence
databases allowed us to use a novel approach for search-
ing functional candidate variants that could account for
the observed association of the CUBN variant with albu-
minuria. Our objective was to identify potential func-
tional candidates in the CUBN gene by combining the
association that was found in Boger et al. [8], with these
newly available datasets. By searching data from the
1000 Genomes Project [14], we found that the reported
p.Ile2984Val (rs1801239) variant has a frequency close to
zero in west Africans, and in Europeans it is actually
part of a large intragenic haplotype. This haplotype com-
prises 19 variants in very high LD, including two add-
itional missense mutations: p.Leu2153Phe (rs62619939)
and p.Glu3002Gly (rs1801240). As a result of this high
LD, these mutations are expected to yield very similar
associations with albuminuria in Europeans. However, in
Yoruba, the missense mutations, as well as the other
SNPs belonging to the European haplotype, are not in
high LD, and have very different allele frequencies.
These differences in allele frequencies and LD patterns
between different populations could leverage the ability
to identify functional variants contributing to different
levels of albuminuria.
Methods
In order to identify SNPs in the CUBN region that are
in high LD (with r2>0.5) with the SNP reported by Boger
et al. (rs1801239, p.Ile2984Val) we utilized the 1000
Genomes Project pilot dataset [14] containing the
complete genome sequences of 59 Africans from Yoruba
(YRI), and 60 individuals of European ancestry from
Utah (CEU). The allele frequency of a SNP is calculated
by the proportion of one type of allelic variant among
the total number of alleles in the sample. We used the
program HaploView [15] which provides visualization of
LD and haplotype block analysis, to yield the LD values
between variants in the region. We identified likely
European (CEU) “haplotypes” containing the tagging
SNP rs1801239 (p.Ile2984Val), and comprising SNPsthat are all in high LD with each other and with this
tagging SNP. We then examined the corresponding
frequencies of these SNPs and their LD patterns in the
YRI sequences, reasoning that differences in LD patterns
between the two populations can guide the search for the
likely causative variant, underlying the functional associ-
ation between the gene CUBN and urinary albumin
excretion.
Results and discussion
Of the 3,862 known SNPs in the 306 Kbp of the CUBN
gene region, we have identified 18 SNPs that are in very
high LD (with r2>0.7, and D’=1) with the reported albumin-
uria associated variant (rs1801239, p.Ile2984Val) in Eur-
opeans (Table 1). This combination of 19 SNPs that can be
considered as one haplotype, spans 50 Kbp between exons
42 and 57 in the CUBN gene, that contains 67 exons.
Among these 19 SNPs is the previously reported variant
p.Ile2984Val (c.8950A>G, rs1801239) [8], as well as two
additional missense mutations: p.Leu2153Phe (c.6459G>C;
rs62619939) and p.Glu3002Gly (c.9005A>G, rs1801240).
The other 16 SNPs in this European CUBN haplotype are
located within introns remote from intron-exon boundar-
ies. The allele frequency of this haplotype in the European
population is about 7%, and therefore according to Hardy-
Weinberg equilibrium, 13.5% of the Europeans may carry
at least one copy of this risk haplotype.
This extended European haplotype was not present
among Yoruba (YRI), as might be expected given the
longer recombination history in Africans [16,17]. An ana-
lysis of the YRI haplotypes in the 1000 Genomes database
revealed significantly different minor allele frequencies of
the missense variants: p.Ile2984Val (rs1801239), 6.7% in
CEU, 0% in YRI; p.Glu3002Gly (rs1801240), 6.7% in
CEU, 21.2% in YRI; and p.Leu2153Phe (rs62619939),
8.3% in CEU, 15.3% in YRI. We successfully validated the
African ancestry allele frequency differences of the var-
iants p.Ile2984Val and p.Glu3002Gly by PCR and Sanger
sequencing in 26 healthy African Americans individuals,
and found minor allele frequencies similar to those com-
puted from the 1000 Genomes Project (p.Ile2984Val
=0%, p.Glu3002Gly =28.8%) (PCR conditions are avail-
able upon request). The minor allele frequency of the
p.Ile2984Val variant reported as being associated with
albuminuria is between 0–1.8% in African ancestry
populations, according to 1000 Genomes Project, Hap-
Map and our own genotyping. This low frequency in
west Africans raises doubts as to whether the attributable
albuminuria risk found for this variant in Europeans
(allele frequency of 6.7%) can explain the same risk
found in African ancestry populations (allele frequency
of ~0%).
Although African Americans were included in the
meta-analysis of Boger et al., the results in that
Table 1 List of the CUBN SNPs in the extended European Haplotype, including the reported albuminuria risk variant







LD with the reported Ile2984Val
Variant in CEU population1
Distance from the reported
Ile2984Val Variant (bp)
r^2 LOD D’
rs1801240 Glu3002Gly 21.1 6.7 1.00 10.36 1 −55
rs1801239 Ile2984Val 0 2 6.7 2 – – – 0
rs74440730 Intronic 2.5 5.8 0.87 8.17 1 1,840
rs79051478 Intronic 0 6.7 1.00 10.36 1 5,557
rs78936062 Intronic 1.7 6.7 1.00 10.36 1 8,825
rs74942409 Intronic 0 6.7 1.00 10.36 1 9,249
rs17343073 Intronic 0 6.7 1.00 10.36 1 13,144
rs78625146 Intronic 0 6.7 1.00 10.36 1 14,787
rs79801018 Intronic 9.3 6.7 1.00 10.36 1 18,607
rs78786782 Intronic 9.3 6.7 1.00 10.36 1 18,723
rs73592376 Intronic 50.8 6.7 1.00 10.36 1 18,735
rs77744173 Intronic 0 6.7 1.00 10.36 1 19,219
rs45619139 Intronic 0 6.7 1.00 10.36 1 21,794
rs74375025 Intronic 0 6.7 1.00 10.36 1 28,612
rs45487598 Intronic 0 8.3 0.79 8.18 1 39,601
17006102-Indel 3 Intronic indel 15.9 7.1 0.88 8.99 1 47,044
17006421-Indel 3 Intronic indel 15.1 7.1 0.88 8.99 1 45,523
rs62619939 Leu2153Phe 15.3 8.3 0.79 8.18 1 48,534
rs111263197 Intronic 17.8 8.3 0.79 8.18 1 49,490
1 Based on 1000 Genomes Project pilot study, CEU n=120, YRI n=118.
2 In larger dataset of HAPMAP (CEU n=226, YRI n=226), the estimated minor allele frequency of rs1801239 was 7.5% in CEU and 1.8% in YRI.
3 This indel (insertion/deletion) variant was reported by 1000 Genomes Project pilot study, but has not been reported elsewhere as yet.
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missense mutations demonstrates association in African
ancestry populations and thereby is possibly more likely
to be functional, since only one (p.Ile2984Val) of the
three missense variants highlighted in our analysis was
actually tested in the Boger et al. study [8]. Moreover,
because African Americans, unlike continental African
individuals, also have about 20% European ancestry [17],
some of the risk variants in this population might be of
European origin.
Interestingly, if the reported p.Ile2984Val variant [8] is
not causative, then we may expect the low value of 0.15%
estimated for percentage of UACR variance explained by
this variant in Europeans to underestimate the actual per-
centage variance explained by the most highly associated
of the relevant variants in African and African American
populations [8]. In YRI 1000 Genomes Project samples, al-
lele frequencies of the risk variants for the SNPs
rs1801240 (p.Glu3002Gly) and rs1801239 (p.Ile2984Val)
are 21.2% and 0% (1.8% according to HapMap), respect-
ively, compared to 6.7% for both SNPs in Europeans.
This leads to an estimated 0.4% variance of UACR
explained in Yoruba if rs1801240 (p.Glu3002Gly) isalbuminuria risk causative, and an order of magnitude
lower expected value of 0.04% or less if rs1801239
(p.Ile2984Val) is risk causative (This calculation is based
on the general formula for variance explained in linear
regression: R2 = β2 * var(X) / var(Y). So if var(X) is
increased from 0.067*0.93=0.062 to 0.212*0.788 =0.167
and beta and var(Y) remain fixed, then R2 grows from
0.15% to 0.4%). Therefore, we can suggest that differ-
ences in allele frequencies and LD patterns between
Africans and Europeans can be used in future association
studies in Africans or African Americans, in which such
newly appreciated candidate SNPs would be directly geno-
typed to inform as to which are the more likely candidate(s)
for functional risk causation.
The mutations p.Ile2984Val and p.Glu3002Gly are
located in exon 57 in a region that is part of the 22nd
CUB domains, out of a total of 27 domains in cubilin
that confer binding ability to a variety of ligands [10]. In
vitro experiments showed that CUB domains 22 through
27 demonstrated calcium dependent binding to megalin
[18]. The third missense mutation in exon 42,
p.Leu2153Phe, is thought to be in the region of CUB do-
main 15, which is adjacent to CUB domains 13–14 that
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protein-binding site [19]. The presence of an extended
haplotype of 50 kbp in Europeans may conceivably reflect
the effect of a selective sweep due to positive selection
pressure under vitamin B12 or other nutritional influ-
ences during human evolution [20,21]. It could be specu-
lated that a particular variant in this European haplotype
might be involved in nutritional selective advantage or
other adaptations during human evolution and migration.
According to PolyPhen2 [22], the mutations p.Ile2984Val
and p.Glu3002Gly are predicted not to alter protein func-
tion, while the missense mutation p.Leu2153Phe is pre-
dicted to impair protein function. Similar programs, such
as SIFT [23] and MutationTaster [24], designated the
three variants as tolerated polymorphisms.
The main limitation of the present study is the lack
of available samples to test the real association of the
suggested candidate variants, since the sample size that
is needed is large, while the effect of the variant is
small. In addition, it is also possible that a variant in a
non-coding region is responsible to the effect found by
Boger et al. [8]. Another possible limitation is that we
based our analysis on publically available sequences,
and deep sequencing methods have limitations related
to alignment problems and base calling. It is also
should be recalled that association is not causation,
and only biological studies can actually prove function-
ality, especially given the complexity of albuminuria
and its relation to both the glomerular filtration and
tubular reabsorption.
The reported association for the CUBN variant,
p.Ile2984Val, led Boger et al. to suggest that levels of al-
buminuria in the general population are determined by
tubular reabsorption acting in concert with glomerular
filtration [8]. The finding of a functional variant, which
alters protein function, would greatly enhance our under-
standing of the mechanisms of albumin excretion in kid-
ney health and disease. Moreover, we have presented a
generic data searching and computational approach that
is based on data mining, bioinformatic and population le-
veraging, which can spawn a wave of association studies
following up on Genome Wide Association Studies
(GWAS) results. A similar approach was successfully
implemented in previous studies in which variants in the
APOL1 gene were found to be highly associated with
non- diabetic end stage kidney disease in African Ameri-
cans [25,26]. Future follow up studies can use existing
well-phenotyped sample sets, with a relatively small
number of genetic tests, and attain far greater statistical
power, by utilizing population ancestry differences in
genetic architecture (LD patterns, allele frequencies, and
population leveraging). This approach can also be applied
to associations reported in other GWAS in common
renal and non-renal disease phenotypes.Conclusion
The current study identified a haplotype in the CUBN
gene that exists only in Europeans and contains three mis-
sense mutations, of which one is the variant p.Ile2984Val
associated with levels of albuminuria. These three muta-
tions (p.Glu3002Gly; p.Ile2984Val; p.Leu2153Phe) have
different LD pattern and allele frequencies in west Afri-
cans, and we suggest using this population to evaluate
which of the three are most likely to be functional. Identi-
fying the true causative has significant implications for
predicting albuminuria-related risks in African-ancestry
individuals and in the general population. Studying the
genetic basis of these variants may also shed light on evo-
lution of the CUBN gene locus with respect to human
evolutionary history.
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